Navigation Links
Oncothyreon regains compliance with NASDAQ listing requirements
Date:3/16/2009

SEATTLE, March 16 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that on March 12, 2009, it received a notice from the NASDAQ Hearings Panel that Oncothyreon had re-gained full compliance with the continued listing standards of The NASDAQ Global Market.

The notice followed a review of Oncothyreon's 2008 financial results, in which Oncothyreon reported that its stockholders' equity as of December 31, 2008 was $20,717,000. Based on this review, the staff of the NASDAQ Hearings Panel determined that Oncothyreon had regained compliance with the continued listing requirements in NASDAQ Marketplace Rule 4450 and notified Oncothyreon that the matter is now closed.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward-Looking Statements

In order to provide our investors with an understanding of our current condition and future prospects, this release contains statements that are forward-looking. These forward-looking statements include statements related to our ability to maintain compliance with the listing standards of The NASDAQ Stock Market. Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the availability and adequacy of financing, our financial condition and results of operations, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon to present at Invest Northwest 2009
2. Oncothyreon reports full year and fourth quarter 2008 financial results
3. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
4. Oncothyreon to present at BIO CEO & Investor Conference 2009
5. Oncothyreon reports third quarter 2008 financial results
6. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
7. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
8. Oncothyreon to present at BIO Investor Forum 2008
9. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
10. Oncothyreon announces prioritization plan for development programs
11. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Next week on May 5 ... first-in-class technologies for tissue stem cell counting and expansion to gene-editing scientists and ... & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention of most gene-editing ...
(Date:4/27/2016)... , ... April 27, 2016 , ... The Pittcon Organizing ... 2019. Chuck has been a volunteer member of Committee since 1987. Since then, ... board of directors and treasurer and was chairman for both the program and exposition ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... Jon Clark has joined the company as an Expert Consultant. Mr. Clark ... industry collaborations and managing the development of small molecule monographs based on analytical ...
(Date:4/27/2016)... , April 27, 2016 MedDay, ... disorders, today announces the appointment of Catherine Moukheibir as Chairman ... MedDay,s previous Chairman, Jean Jacques Garaud , who contributed ... change is effective immediately. Catherine started her career ... and London .  She held ...
Breaking Biology Technology:
(Date:3/21/2016)... 2016 Unique technology combines ... superior security   Xura, Inc. ... secure digital communications services, today announced it is working ... enterprise customers, particularly those in the Financial Services Sector, ... authentication within a mobile app, alongside, and in combination ...
(Date:3/14/2016)... Florida , March 14, 2016 ... the growing mobile commerce market, announces the airing of a ... channels starting the week of March 21 st .  The ... CNBC, including its popular Squawk on the Street show. ... focused on the growing mobile commerce market, announces the airing ...
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
Breaking Biology News(10 mins):